Provided by Tiger Trade Technology Pte. Ltd.

Armata Pharmaceuticals, Inc.

3.31
-0.3600-9.81%
Post-market: 3.310.00000.00%19:30 EDT
Volume:76.46K
Turnover:263.77K
Market Cap:123.07M
PE:-0.63
High:3.78
Open:3.67
Low:3.28
Close:3.67
52wk High:16.34
52wk Low:2.94
Shares:37.18M
Float Shares:11.88M
Volume Ratio:0.70
T/O Rate:0.64%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.2744
EPS(LYR):-4.8000
ROE:-3439.35%
ROA:-25.83%
PB:-0.53
PE(LYR):-0.69

Loading ...

JonesTrading Reaffirms Their Buy Rating on Armata Pharmaceuticals (ARMP)

TIPRANKS
·
Sep 27

Armata Pharmaceuticals Price Target Maintained with a $15.00/Share by HC Wainwright & Co.

Dow Jones
·
Sep 23

Armata Gets $3.7M in Additional Funding from Defense Dept. for Bacterial Infection Treatment

Dow Jones
·
Sep 23

Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-Sa02 Phase 3 Development

THOMSON REUTERS
·
Sep 23

Armata Says AP-SA02 Genetic Diversity May Boost Killing of Some Staph Aureus Isolates in Clinical Testing

Reuters
·
Sep 21

Armata Pharma Shares Rise on FDA Breakthrough Therapy Designation for Antibacterial Treatment

Dow Jones
·
Sep 14

Armata Says FDA Grants Breakthrough Therapy Designation for AP-SA02 in Complicated Staph Aureus Bacteremia

Reuters
·
Sep 14

Armata Pharmaceuticals, - to Initiate Phase 3 Superiority Study of AP-Sa02 in H2 2026

THOMSON REUTERS
·
Sep 14

Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-Sa02

THOMSON REUTERS
·
Sep 14

Armata Pharmaceuticals CEO Deborah Birx Presents at H.C. Wainwright Global Investment Conference

Reuters
·
Sep 10

Armata Says Inhaled Phage Candidate AP-PA02 Completes Phase 2 Trials in Cystic Fibrosis, Bronchiectasis Patients

Reuters
·
Sep 03

Armata Pharmaceuticals Q2 EPS $(0.27) Beats $(0.45) Estimate, Sales $2.510M Beat $420.000K Estimate

Benzinga Earnings
·
Aug 13

Armata Swings to FY26 Q2 Net Income of $74.14 Million; Operating Loss Widens to $10.31 Million

Reuters
·
Aug 13

Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update

THOMSON REUTERS
·
Aug 13

Armata Pharmaceuticals, - Promotes David House to Chief Financial Officer

THOMSON REUTERS
·
Aug 13

Analysts Offer Insights on Healthcare Companies: Palvella Therapeutics (PVLA) and Armata Pharmaceuticals (ARMP)

TIPRANKS
·
Jul 20

Armata Pharmaceuticals - Appoints David House as Chief Financial Officer Effective July 17, 2026 - SEC Filing

THOMSON REUTERS
·
Jul 20

Armata provides update on AP-SA02 studies

TIPRANKS
·
Jul 20

Armata Pharmaceuticals Names David House CFO

Reuters
·
Jul 20

Armata Pharmaceuticals Announces Press Release Availability

Reuters
·
Jul 13